Alkermes plc(ALKS)Earnings, Financials & Key Ratios

ALKS•NASDAQ

$36.25

$6.12B mkt cap·25.3× P/E·Price updated May 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryCommercial Specialty Pharma

AboutAlkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Show more

Revenue$1.48B-5.2%
EBITDA$281M-37.4%
Net Income$242M-34.2%
EPS (Diluted)1.43-34.1%
Gross Margin86.31%+2.4%
EBITDA Margin19.05%-33.9%
Operating Margin17.21%-36.3%
Net Margin16.37%-30.5%
ROE14.72%-46.5%
ROIC18.87%-29.2%
Debt/Equity0.04-25.4%
Interest Coverage24.74+19.8%

Technical→

ALKS Key Insights

Alkermes plc (ALKS) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free
✓Excellent 3Y average ROE of 24.6%
✓Strong Piotroski F-Score: 7/9
✓FCF machine: 32.5% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Trading near 52-week high

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

ALKS Price & Volume

Alkermes plc (ALKS) stock price & volume — 10-year historical chart

Loading chart...

ALKS Growth Metrics

Alkermes plc (ALKS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years8.91%

5 Years7.28%

3 Years9.9%

TTM-5.25%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-34.16%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-34.1%

Return on Capital

10 Years2.38%

5 Years14.66%

3 Years22.44%

Last Year14.2%

ALKS Recent Earnings

Alkermes plc (ALKS) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 7/12 qtrs (58%)●Beat Revenue 10/12 qtrs (83%)

Q2 2026Latest

May 5, 2026

EPS

$0.40

Est $0.57

+29.8%

Revenue

$393M

Est $363M

+8.2%

Q1 2026

Feb 25, 2026

EPS

$0.34

Est $0.43

-20.9%

Revenue

$385M

Est $379M

+1.5%

Q4 2025

Oct 28, 2025

EPS

$0.49

Est $0.42

+16.7%

Revenue

$394M

Est $380M

+3.8%

Q3 2025

Jul 29, 2025

EPS

$0.52

Est $0.41

+26.8%

Revenue

$391M

Est $355M

+10.2%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 5, 2026	$0.40vs $0.57+29.8%	$393Mvs $363M+8.2%
Q1 2026	Feb 25, 2026	$0.34vs $0.43-20.9%	$385Mvs $379M+1.5%
Q4 2025	Oct 28, 2025	$0.49vs $0.42+16.7%	$394Mvs $380M+3.8%
Q3 2025	Jul 29, 2025	$0.52vs $0.41+26.8%	$391Mvs $355M+10.2%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
INVAInnoviva, Inc.Direct Competitor	1.69B	22.65	6.86	18.52%	65.38%	23.12%	11.58%
SUPNSupernus Pharmaceuticals, Inc.Direct Competitor	2.82B	49.03	-72.10	8.63%	-3.74%	-2.73%	1.63%	0.04
ACADACADIA Pharmaceuticals Inc.Direct Competitor	3.78B	22.35	16.43	31.85%	24.94%	28.47%	4.16%	0.07
AXSMAxsome Therapeutics, Inc.Direct Competitor	11.41B	223.06	-60.61	65.55%	-26.59%	-260.01%		2.73
INTRInter & Co, Inc.Direct Competitor	2.46B	7.59	18.11	27.12%	9.34%	12.37%	26.73%	1.31
JAZZJazz Pharmaceuticals plcProduct Competitor	13.32B	212.26	-36.35	4.88%	0.66%	0.71%	9.74%	1.26
TEVATeva Pharmaceutical Industries LimitedProduct Competitor	41.76B	35.86	29.88	4.31%	9.02%	20.69%	2.75%	2.20
BHCBausch Health Companies Inc.Product Competitor	2.11B	5.64	13.12	8.53%	-11.27%	5.88%	47.62%	56.36

Compare ALKS vs Peers

Alkermes plc (ALKS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs INVA

Most directly comparable listed peer for ALKS.

Scale Benchmark

vs LLY

Larger-name benchmark to compare ALKS against a more recognizable public peer.

Peer Set

Compare Top 5

vs INVA, SUPN, ACAD, AXSM

ALKS Income Statement

Alkermes plc (ALKS) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	903.37M	1.09B	1.17B	1.04B	1.17B	1.11B	1.66B	1.56B	1.48B
Revenue Growth %	21.15%	21.13%	7.01%	-11.29%	13%	-5.28%	49.61%	-6.36%	-5.25%
Cost of Goods Sold	154.75M	176.42M	180.38M	178.32M	197.32M	218.07M	253.04M	245.33M	202.06M
COGS % of Revenue	17.13%	16.12%	15.41%	17.17%	16.81%	19.61%	15.21%	15.75%	13.69%
Gross Profit	748.63M▲ 0%	917.85M▲ 22.6%	990.56M▲ 7.9%	860.44M▼ 13.1%	976.43M▲ 13.5%	893.73M▼ 8.5%	1.41B▲ 57.8%	1.31B▼ 7.0%	1.27B▼ 2.9%
Gross Margin %	82.87%	83.88%	84.59%	82.83%	83.19%	80.39%	84.79%	84.25%	86.31%
Gross Profit Growth %	22.01%	22.61%	7.92%	-13.14%	13.48%	-8.47%	57.81%	-6.95%	-2.93%
Operating Expenses	896.53M	1.02B	1.17B	972.87M	878.68M	899.82M	996.25M	891.66M	1.02B
OpEx % of Revenue	99.24%	92.94%	99.58%	93.66%	74.86%	80.93%	59.89%	57.24%	69.1%
Selling, General & Admin	421.58M	526.41M	599.45M	538.83M	549.61M	590.75M	689.75M	645.24M	701.52M
SG&A % of Revenue	46.67%	48.11%	51.19%	51.87%	46.83%	53.13%	41.47%	41.42%	47.53%
Research & Development	412.89M	425.41M	512.83M	394.59M	290.92M	272.7M	270.81M	245.33M	323.96M
R&D % of Revenue	45.71%	38.88%	43.8%	37.99%	24.79%	24.53%	16.28%	15.75%	21.95%
Other Operating Expenses	62.06M	65.17M	53.76M	39.45M	38.15M	36.36M	35.69M	1.1M	-5.6M
Operating Income	-147.9M▲ 0%	-99.13M▲ 33.0%	-175.48M▼ 77.0%	-112.43M▲ 35.9%	97.75M▲ 186.9%	-6.09M▼ 106.2%	414.12M▲ 6901.1%	420.64M▲ 1.6%	253.96M▼ 39.6%
Operating Margin %	-16.37%	-9.06%	-14.99%	-10.82%	8.33%	-0.55%	24.9%	27%	17.21%
Operating Income Growth %	29.12%	32.98%	-77.02%	35.93%	186.94%	-106.23%	6901.15%	1.57%	-39.63%
EBITDA	-49.38M	4.53M	-95.07M	-30.57M	176.4M	71.77M	489.05M	449.17M	281.12M
EBITDA Margin %	-5.47%	0.41%	-8.12%	-2.94%	15.03%	6.46%	29.4%	28.84%	19.05%
EBITDA Growth %	56.84%	109.18%	-2197.66%	67.84%	676.97%	-59.31%	581.38%	-8.15%	-37.41%
D&A (Non-Cash Add-back)	98.52M	103.66M	80.41M	81.85M	78.65M	77.86M	74.93M	28.53M	27.16M
EBIT	-131.27M	-111.53M	-183.46M	-87.88M	98.95M	-18.09M	444.55M	466.33M	303.73M
Net Interest Income	-7.36M	-6.2M	375K	-1.7M	-8.81M	-5.41M	7.82M	19.87M	33.03M
Interest Income	4.65M	9.24M	13.98M	6.96M	2.41M	7.63M	30.85M	42.45M	45.3M
Interest Expense	12.01M	15.44M	13.6M	8.66M	11.22M	13.04M	23.03M	22.58M	12.28M
Other Income/Expense	4.63M	-27.84M	-21.58M	15.89M	-10.02M	-25.04M	7.4M	23.11M	37.49M
Pretax Income	-143.27M▲ 0%	-126.97M▲ 11.4%	-197.06M▼ 55.2%	-96.54M▲ 51.0%	87.73M▲ 190.9%	-31.13M▼ 135.5%	421.52M▲ 1454.1%	443.75M▲ 5.3%	291.45M▼ 34.3%
Pretax Margin %	-15.86%	-11.6%	-16.83%	-9.29%	7.47%	-2.8%	25.34%	28.49%	19.75%
Income Tax	14.67M	12.34M	-436K	14.32M	11.33M	2.02M	-97.64M	71.61M	49.79M
Effective Tax Rate %	-10.24%	-9.72%	0.22%	-14.84%	12.91%	-6.5%	-23.16%	16.14%	17.08%
Net Income	-157.94M▲ 0%	-139.31M▲ 11.8%	-196.62M▼ 41.1%	-110.86M▲ 43.6%	-48.17M▲ 56.6%	-158.27M▼ 228.6%	355.76M▲ 324.8%	367.07M▲ 3.2%	241.66M▼ 34.2%
Net Margin %	-17.48%	-12.73%	-16.79%	-10.67%	-4.1%	-14.24%	21.39%	23.57%	16.37%
Net Income Growth %	24.23%	11.8%	-41.14%	43.62%	56.55%	-228.57%	324.78%	3.18%	-34.16%
Net Income (Continuing)	-157.94M	-139.31M	-196.62M	-110.86M	76.4M	-33.15M	519.16M	372.14M	241.66M
Discontinued Operations	0	0	0	0	-124.57M	-125.11M	-163.4M	-5.07M	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)	-1.03▲ 0%	-0.90▲ 12.6%	-1.25▼ 38.9%	-0.70▲ 44.0%	-0.30▲ 57.1%	-0.97▼ 223.3%	2.10▲ 316.5%	2.17▲ 3.3%	1.43▼ 34.1%
EPS Growth %	25.36%	12.62%	-38.89%	44%	57.14%	-223.33%	316.49%	3.33%	-34.1%
EPS (Basic)	-1.03	-0.90	-1.25	-0.70	-0.30	-0.97	2.14	2.22	1.47
Diluted Shares Outstanding	153.41M	155.11M	157.05M	158.8M	160.94M	163.74M	169.73M	169.2M	168.74M
Basic Shares Outstanding	153.41M	155.11M	157.05M	158.8M	160.94M	163.74M	166.22M	165.39M	164.7M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

ALKS Balance Sheet

Alkermes plc (ALKS) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	966.06M	983.25M	961.97M	1.11B	1.06B	1.13B	1.49B	1.42B	1.93B
Cash & Short-Term Investments	590.72M	539.29M	534.98M	635.03M	536.31M	608.47M	773.49M	751.67M	1.32B
Cash Only	191.3M	266.76M	203.77M	272.96M	337.54M	292.47M	457.47M	291.15M	1.12B
Short-Term Investments	242.21M	272.53M	331.21M	362.07M	198.77M	315.99M	316.02M	460.52M	199.65M
Accounts Receivable	233.59M	300.45M	265.47M	289.54M	326.56M	296.9M	333.18M	389.52M	334.02M
Days Sales Outstanding	94.38	100.22	82.75	101.74	101.55	97.47	73.11	91.28	82.61
Inventory	93.28M	90.2M	101.8M	125.74M	150.34M	181.42M	186.41M	182.89M	196.63M
Days Inventory Outstanding	220.01	186.61	205.99	257.38	278.08	303.66	268.89	272.1	355.19
Other Current Assets	0	0	0	0	0	43.53M	192.43M	91.28M	79.09M
Total Non-Current Assets	831.17M	841.75M	843.43M	838.76M	962.32M	833.67M	650.72M	640.21M	601.09M
Property, Plant & Equipment	284.74M	309.99M	374.55M	481.72M	456.68M	320.46M	318.4M	311.81M	298.93M
Fixed Asset Turnover	3.17x	3.53x	3.13x	2.16x	2.57x	3.47x	5.22x	5.00x	4.94x
Goodwill	92.87M	92.87M	92.87M	92.87M	92.87M	83.03M	83.03M	83.03M	0
Intangible Assets	256.17M	191M	150.64M	111.19M	74.04M	37.68M	1.99M	890K	83.84M
Long-Term Investments	157.21M	80.74M	79.39M	24.78M	229.43M	131.61M	39.89M	73.15M	145K
Other Non-Current Assets	-58.38M	81.34M	49.42M	41.97M	27.45M	146.32M	11.52M	16.5M	49.1M
Total Assets	1.8B▲ 0%	1.83B▲ 1.5%	1.81B▼ 1.1%	1.95B▲ 8.0%	2.02B▲ 3.8%	1.96B▼ 3.0%	2.14B▲ 8.8%	2.06B▼ 3.8%	2.53B▲ 23.1%
Asset Turnover	0.50x	0.60x	0.65x	0.53x	0.58x	0.57x	0.78x	0.76x	0.58x
Asset Growth %	4.1%	1.55%	-1.07%	7.99%	3.83%	-2.99%	8.77%	-3.78%	23.09%
Total Current Liabilities	291.12M	339.77M	391.11M	438.26M	471.29M	497.74M	520.22M	465.2M	543.44M
Accounts Payable	55.53M	39.77M	54.26M	46.03M	55.72M	32.84M	65.65M	45.63M	107.95M
Days Payables Outstanding	130.97	82.28	109.79	94.23	103.07	54.97	94.7	67.89	195
Short-Term Debt	3M	2.84M	2.84M	2.84M	3M	3M	3M	0	6.75M
Deferred Revenue (Current)	1.96M	3.17M	6.77M	7.51M	6.34M	6.82M	2.73M	1.25M	0
Other Current Liabilities	176.07M	226.38M	72.07M	71.18M	77.26M	84.93M	359.99M	70.96M	428.74M
Current Ratio	3.32x	2.89x	2.46x	2.53x	2.25x	2.27x	2.86x	3.04x	3.55x
Quick Ratio	3.00x	2.63x	2.20x	2.25x	1.93x	1.91x	2.50x	2.65x	3.19x
Cash Conversion Cycle	183.42	204.55	178.95	264.89	276.56	346.15	247.3	295.48	242.79
Total Non-Current Liabilities	303.3M	313.95M	328.85M	444.49M	440.61M	422.48M	413.32M	125.39M	167.52M
Long-Term Debt	278.44M	276.46M	274.3M	272.12M	292.8M	290.27M	287.73M	0	0
Capital Lease Obligations	0	0	5.34M	119.46M	104.16M	76.29M	75.71M	69.37M	63.25M
Deferred Tax Liabilities	0	0	0	0	0	0	-4.78M	0	43.26M
Other Non-Current Liabilities	19.2M	27.96M	27.14M	36.51M	32.16M	55.93M	49.88M	56.02M	61.01M
Total Liabilities	594.42M	653.72M	719.96M	882.75M	911.9M	920.23M	933.54M	590.59M	710.96M
Total Debt	281.44M	279.31M	290.95M	410.16M	416.21M	379.44M	372.19M	75.54M	70M
Net Debt	90.14M	12.55M	87.17M	137.2M	78.66M	86.96M	-85.28M	-215.61M	-1.05B
Debt / Equity	0.23x	0.24x	0.27x	0.38x	0.37x	0.36x	0.31x	0.05x	0.04x
Debt / EBITDA	-	61.63x	-	-	2.36x	5.29x	0.76x	0.17x	0.25x
Net Debt / EBITDA	-	2.77x	-	-	0.45x	1.21x	-0.17x	-0.48x	-3.73x
Interest Coverage	-10.93x	-7.22x	-13.49x	-10.15x	8.82x	-1.39x	19.30x	20.65x	24.74x
Total Equity	1.2B▲ 0%	1.17B▼ 2.6%	1.09B▼ 7.3%	1.07B▼ 1.7%	1.11B▲ 4.3%	1.04B▼ 6.2%	1.2B▲ 15.2%	1.46B▲ 21.8%	1.82B▲ 24.2%
Equity Growth %	-0.55%	-2.62%	-7.33%	-1.7%	4.27%	-6.19%	15.23%	21.81%	24.19%
Book Value per Share	7.84	7.55	6.91	6.72	6.91	6.37	7.09	8.66	10.78
Total Shareholders' Equity	1.2B	1.17B	1.09B	1.07B	1.11B	1.04B	1.2B	1.46B	1.82B
Common Stock	1.56M	1.58M	1.6M	1.62M	1.66M	1.69M	1.73M	1.77M	1.81M
Retained Earnings	-1.04B	-1.19B	-1.38B	-1.49B	-1.54B	-1.7B	-1.34B	-976.46M	-734.79M
Treasury Stock	-89.35M	-108.97M	-118.39M	-126.09M	-142.66M	-160.86M	-189.34M	-419.25M	-450.29M
Accumulated OCI	-3.79M	-3.28M	-1.82M	-1.35M	-3.72M	-10.89M	-3.11M	-1.97M	-2.1M
Minority Interest	0	0	0	0	0	0	0	0	0

ALKS Cash Flow Statement

Alkermes plc (ALKS) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	19.19M	99.28M	72.08M	82.84M	101.72M	21.04M	401.35M	439.12M	520.75M
Operating CF Margin %	2.12%	9.07%	6.16%	7.98%	8.67%	1.89%	24.13%	28.19%	35.28%
Operating CF Growth %	130.08%	417.36%	-27.4%	14.94%	22.78%	-79.31%	1807.21%	9.41%	18.59%
Net Income	-157.94M	-139.31M	-196.62M	-110.86M	-48.17M	-158.27M	355.76M	367.07M	241.66M
Depreciation & Amortization	98.52M	103.66M	80.41M	81.85M	78.65M	77.86M	74.93M	28.53M	27.16M
Stock-Based Compensation	83.92M	105.36M	100.98M	90.16M	87.62M	94.25M	100.91M	96.64M	0
Deferred Taxes	7.23M	10.62M	-319K	9.98M	5.08M	-32.8M	-99.9M	40.52M	28.77M
Other Non-Cash Items	-7.66M	26.37M	22.22M	-1.43M	4.08M	27.28M	6.33M	4.51M	104.03M
Working Capital Changes	-4.88M	-7.42M	65.41M	13.13M	-25.55M	12.71M	-36.66M	-98.15M	119.12M
Change in Receivables	-42.49M	-58.63M	29.98M	-18.05M	-38.01M	25.25M	-44.51M	-56.34M	30.17M
Change in Inventory	-30.19M	-2.67M	-13.08M	-22.93M	-24.77M	-31.02M	-2.71M	3.09M	-14.06M
Change in Payables	72.66M	46.74M	34.85M	59.04M	43.31M	15.53M	23.01M	-57.97M	100.89M
Cash from Investing	-18.36M	-22.2M	-141.83M	-11.48M	-66.2M	-64.54M	53.36M	-111.31M	295.5M
Capital Expenditures	-51.3M	-69.43M	-90.94M	-42.22M	-29.02M	-38.26M	-48.05M	-33.48M	-40.42M
CapEx % of Revenue	5.68%	6.34%	7.77%	4.06%	2.47%	3.44%	2.89%	2.15%	2.74%
Acquisitions	162K	507K	-7.97M	2.75M	-713K	485K	0	97.98M	2.79M
Investments	-	-	-	-	-	-	-	-	-
Other Investing	162K	507K	10M	4.53M	8.94M	1.27M	354K	461K	0
Cash from Financing	4.08M	-1.62M	6.76M	-2.17M	29.07M	-1.57M	-289.71M	-494.14M	12.38M
Debt Issued (Net)	0	-743K	-2.84M	-2.84M	20.32M	-3M	-3M	-291.79M	0
Equity Issued (Net)	0	0	9.61M	672K	8.75M	1.43M	-11.71M	-200.28M	12.38M
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-16.43M	-19.62M	-9.32M	-7.7M	-16.57M	-18.2M	-28.47M	-200.28M	-31.03M
Other Financing	4.08M	-877K	0	0	0	0	-275M	-2.06M	0
Net Change in Cash	4.92M▲ 0%	75.47M▲ 1434.5%	-62.99M▼ 183.5%	69.19M▲ 209.8%	64.58M▼ 6.7%	-45.07M▼ 169.8%	165M▲ 466.1%	-166.32M▼ 200.8%	828.63M▲ 598.2%
Free Cash Flow	-32.11M▲ 0%	29.85M▲ 193.0%	-18.86M▼ 163.2%	40.62M▲ 315.3%	72.69M▲ 79.0%	-17.21M▼ 123.7%	353.31M▲ 2152.8%	405.64M▲ 14.8%	480.33M▲ 18.4%
FCF Margin %	-3.55%	2.73%	-1.61%	3.91%	6.19%	-1.55%	21.24%	26.04%	32.55%
FCF Growth %	70.12%	192.96%	-163.2%	315.34%	78.95%	-123.68%	2152.79%	14.81%	18.41%
FCF per Share	-0.21	0.19	-0.12	0.26	0.45	-0.11	2.08	2.40	2.85
FCF Conversion (FCF/Net Income)	-0.12x	-0.71x	-0.37x	-0.75x	-2.11x	-0.13x	1.13x	1.20x	2.15x
Interest Paid	11.14M	12.53M	0	8.29M	6.9M	13.56M	22.75M	23.01M	0
Taxes Paid	2.99M	754K	0	620K	1.89M	20.75M	44.24M	2.59M	0

ALKS Key Ratios

Alkermes plc (ALKS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-16.52%	-13.1%	-11.74%	-17.43%	-10.3%	-4.42%	-14.68%	31.67%	27.52%	14.72%
Return on Invested Capital (ROIC)	-11.22%	-8.53%	-6%	-11.17%	-7.1%	6.12%	-0.39%	27.63%	26.66%	18.87%
Gross Margin	82.28%	82.87%	83.88%	84.59%	82.83%	83.19%	80.39%	84.79%	84.25%	86.31%
Net Margin	-27.95%	-17.48%	-12.73%	-16.79%	-10.67%	-4.1%	-14.24%	21.39%	23.57%	16.37%
Debt / Equity	0.23x	0.23x	0.24x	0.27x	0.38x	0.37x	0.36x	0.31x	0.05x	0.04x
Interest Coverage	-13.40x	-10.93x	-7.22x	-13.49x	-10.15x	8.82x	-1.39x	19.30x	20.65x	24.74x
FCF Conversion	0.31x	-0.12x	-0.71x	-0.37x	-0.75x	-2.11x	-0.13x	1.13x	1.20x	2.15x
Revenue Growth	18.68%	21.15%	21.13%	7.01%	-11.29%	13%	-5.28%	49.61%	-6.36%	-5.25%

ALKS SEC Filings & Documents

Alkermes plc (ALKS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 5, 2026·SEC

Material company update

Feb 25, 2026·SEC

Material company update

Feb 25, 2026·SEC

10-K Annual Reports

FY 2026

Feb 25, 2026·SEC

FY 2025

Feb 12, 2025·SEC

10-Q Quarterly Reports

FY 2026

May 5, 2026·SEC

FY 2025

Oct 28, 2025·SEC

FY 2025

Jul 29, 2025·SEC

ALKS Frequently Asked Questions

Alkermes plc (ALKS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Alkermes plc (ALKS) reported $1.48B in revenue for fiscal year 2025. This represents a 7344% increase from $19.8M in 1996.

Alkermes plc (ALKS) saw revenue decline by 5.2% over the past year.

Yes, Alkermes plc (ALKS) is profitable, generating $241.7M in net income for fiscal year 2025 (16.4% net margin).

Dividend & Returns

Alkermes plc (ALKS) has a return on equity (ROE) of 14.7%. This is reasonable for most industries.

Alkermes plc (ALKS) generated $480.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More ALKS

Alkermes plc (ALKS) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Alkermes plc(ALKS)Earnings, Financials & Key Ratios

ALKS Key Insights

✓Strengths

✗Weaknesses

ALKS Price & Volume

ALKS Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

ALKS Recent Earnings

ALKS Peer Comparison

Compare ALKS vs Peers

vs INVA

vs LLY

Compare Top 5

ALKS Income Statement

ALKS Balance Sheet

ALKS Cash Flow Statement

ALKS Key Ratios

ALKS SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

ALKS Frequently Asked Questions

Explore More ALKS

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation